Sarcopenia, Osteoporosis
Conditions
Keywords
Sarcopenia, Osteoporosis, Cognition, Inflammation
Brief summary
Bovine colostrum is the initial milk secreted by cows during the first day after calving. Colostrum is high in protein and contains a number of substances that have potential to be beneficial for the immune system. Preliminary studies about effects of colostrum supplementation show its potential for increasing human exercise performance; however, more evidence across the lifespan is required to confirm effects and to understand mechanisms of action. The objectives are to determine the effect of 8 weeks of bovine colostrum supplementation, compared to whey protein supplementation on the following dependent variables in men and women 50 years and older while participating in a resistance-training program: * muscle mass * strength * blood levels of growth factors and markers of inflammation * urine levels of muscle and bone catabolic markers * tests of cognitive ability It is hypothesized that bovine colostrum supplementation will result in greater increases in muscle mass, strength, blood IGF-1 levels (an anabolic hormone), and cognitive ability, and greater reductions in inflammation, and markers of muscle and bone catabolism, compared to placebo.
Interventions
DIETARY_SUPPLEMENTBovine colostrum
DIETARY_SUPPLEMENTWhey protein
Sponsors
Mitacs
University of Saskatchewan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Men or women 50 y or older
Exclusion criteria
* Milk allergies * Contraindications to exercise as indicated by the Physical Activity Readiness Questionnaire
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change from baseline in lean tissue mass at 8 weeks | baseline and 8 weeks | Lean tissue mass assessed by dual energy x-ray absorptiometry |
| Change from baseline in Upper body strength at 8 weeks | baseline and 8 weeks | Bench Press Strength |
| Change from baseline in Lower body strength at 8 weeks | baseline and 8 weeks | Leg press strength |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in muscle catabolism at 8 weeks | baseline and 8 weeks | Urinary 3-methylhistidine levels |
| Change from baseline in bone catabolism at 8 weeks | Baseline and 8 weeks | Urinary cross-linked N-telopeptides of type I collagen |
| Change from baseline in Insulin like growth factor-1 at 8 weeks | baseline and 8 weeks | IGF-1 from serum |
| Change from baseline in inflammation at 8 weeks | baseline and 8 weeks | Serum cytokine markers of inflammation (IL-6 and TNF-alpha) |
| Change from baseline in cognitive ability at 8 weeks | baseline and 8 weeks | The Telephone Interview of Cognitive Status |
| Number of Participants with Adverse Events as a Measure of Safety and Number of Participants with Adverse Events as a Measure of Safety and Tolerability | continuously throughout 8 weeks | Adverse events collected on adverse event forms |
| Change from baseline in upper body muscle thickness at 8 weeks | baseline and 8 weeks | Muscle thickness of the elbow flexors assessed by ultrasound |
| Change from baseline in lower body muscle thickness at 8 weeks | baseline and 8 weeks | Knee extensors muscle thickness assessed by ultrasound |
Countries
Canada
Outcome results
None listed